KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBIT (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed EBIT for 4 consecutive years, with -$178.1 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EBIT rose 24.05% year-over-year to -$178.1 million, compared with a TTM value of -$864.4 million through Dec 2023, up 60.87%, and an annual FY2025 reading of -$313.6 million, up 43.98% over the prior year.
  • EBIT was -$178.1 million for Q4 2023 at Ginkgo Bioworks Holdings, up from -$286.4 million in the prior quarter.
  • Across five years, EBIT topped out at -$5.3 million in Q2 2021 and bottomed at -$1.7 billion in Q4 2021.
  • Average EBIT over 4 years is -$356.6 million, with a median of -$199.9 million recorded in 2023.
  • Peak annual rise in EBIT hit 86.52% in 2022, while the deepest fall reached 12096.98% in 2022.
  • Year by year, EBIT stood at -$55.9 million in 2020, then crashed by 3012.24% to -$1.7 billion in 2021, then skyrocketed by 86.52% to -$234.5 million in 2022, then increased by 24.05% to -$178.1 million in 2023.
  • Business Quant data shows EBIT for DNA at -$178.1 million in Q4 2023, -$286.4 million in Q3 2023, and -$184.2 million in Q2 2023.